EGFR conjunct FSCN1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Emerging evidence indicates that Fascin-1 (FSCN1) may possess a causal role in the development of several types of cancers and serves as a novel biomarker of aggressiveness in certain carcinomas. However, the regulatory mechanism of FSCN1 in triple-negative breast cancer (TNBC) cell invasion and mig...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chao-Qun, Li, Yang, Huang, Bi-Fei, Zhao, Yong-Ming, Yuan, Hui, Guo, Dongfang, Su, Chen-Ming, Hu, Gui-Nv, Wang, Qian, Long, Tengyun, Wang, Yan, Tang, Chih-Hsin, Li, Xiaoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688137/
https://www.ncbi.nlm.nih.gov/pubmed/29142206
http://dx.doi.org/10.1038/s41598-017-15939-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5688137/
https://www.ncbi.nlm.nih.gov/pubmed/29142206
http://dx.doi.org/10.1038/s41598-017-15939-9

Ejemplares similares